Product：Crysvita®（Burosumab Injection）

Indication:

For the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older, and for the treatment of FGF23-related hypophosphatemia in adults with tumor-induced osteomalacia (TIO) that cannot be curatively resected or localized.

Product：Poteligeo®（Mogamulizumab Injection）

Indication:

For the treatment of adult patients with relapsed or refractory Sézary syndrome (SS) or last stage (III/IV) mycosis fungoides (MF) who have received prior systemic therapy.

Product：RAVICTI® (Glycerol Phenylbutyrate Oral Liquid)

Indications:

This product is indicated for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I, ornithine carbamoyltransferase, argininosuccinate synthetase, argininosuccinate lyase, arginase I and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. Glycerol phenylbutyrate must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).